For research use only. Not for therapeutic Use.
BBIQ is a imidazoquinoline compound and a potent and selectively toll-like receptor 7 (TLR7) agonist with an EC50 of 59.1 nM for human TLR7. BBIQ is a powerful vaccine adjuvant that enhances innate immune responses[1][2].
BBIQ induces IFN-α in human PBMCs (520 pg/mL at 5 µg/mL)[1].
In mice treated with Chloroquine (CQ) alone, parasite (P. berghei ANKA) appearesd on Day 17 and all mice of this group died by Day 21. Whereas, mice treated with BBIQ along with CQ exhibits no appearance of parasite till Day 23. Frequencies of T cells (CD3+, CD4+and CD8+) and T regulatory cells (CD4+, CD25 +and FoxP3+) are lower in brain of BBIQ + CQ treated mice as compared to BBIQ alone and CQ alone treated mice on Day 10. Inhibition of infiltration of inflammatory T cells and activation of T helper and T cytotoxic cells against the parasite is observed in the mice treated with this combination therapy. Serum levels of IFN-γ and IL-12 are higher on same day in mice treated with BBIQ + CQ which reveals the generation of strong Th1 immune response in mice against the infection[1].
| Catalog Number | I016680 |
| CAS Number | 1229024-57-0 |
| Synonyms | 1-benzyl-2-butylimidazo[4,5-c]quinolin-4-amine |
| Molecular Formula | C21H22N4 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H22N4/c1-2-3-13-18-24-19-20(25(18)14-15-9-5-4-6-10-15)16-11-7-8-12-17(16)23-21(19)22/h4-12H,2-3,13-14H2,1H3,(H2,22,23) |
| InChIKey | CQBDMXYZNLJUFT-UHFFFAOYSA-N |
| SMILES | CCCCC1=NC2=C(N1CC3=CC=CC=C3)C4=CC=CC=C4N=C2N |
| Reference | [1]. Saroa R, et al. Efficacy of TLR7 agonistic imidazoquinoline as immunochemotherapeutic agent against P. Berghei ANKA infected rodent host. Bioorg Med Chem Lett. 2019 May 1;29(9):1099-1105. [2]. Kaushik D, et al. BBIQ, a pure TLR7 agonist, is an effective influenza vaccine adjuvant. Hum Vaccin Immunother. 2020 Apr 16:1-8. |
